177 related articles for article (PubMed ID: 10679403)
21. Complement receptor type 1.
Ross GD
Curr Top Microbiol Immunol; 1992; 178():31-44. PubMed ID: 1424775
[No Abstract] [Full Text] [Related]
22. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
23. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
24. Positively charged amino acids at the interface between alpha-chain CCP1 and CCP2 of C4BP are required for regulation of the classical C3-convertase.
Blom AM; Zadura AF; Villoutreix BO; Dahlbäck B
Mol Immunol; 2000 Jun; 37(8):445-53. PubMed ID: 11090879
[TBL] [Abstract][Full Text] [Related]
25. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression.
Spiller OB; Moretto G; Kim SU; Morgan BP; Devine DV
J Neuroimmunol; 1996 Dec; 71(1-2):97-106. PubMed ID: 8982108
[TBL] [Abstract][Full Text] [Related]
26. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies.
Seya T; Matsumoto M; Hara T; Hatanaka M; Masaoka T; Akedo H
Leuk Lymphoma; 1994 Feb; 12(5-6):395-400. PubMed ID: 7514063
[TBL] [Abstract][Full Text] [Related]
27. Membrane-associated proteins regulating the complement system: functions and deficiencies.
Schieren G; Hänsch GM
Int Rev Immunol; 1993; 10(1):87-101. PubMed ID: 7688019
[No Abstract] [Full Text] [Related]
28. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.
Christiansen D; Devaux P; Réveil B; Evlashev A; Horvat B; Lamy J; Rabourdin-Combe C; Cohen JH; Gerlier D
J Virol; 2000 May; 74(10):4672-8. PubMed ID: 10775604
[TBL] [Abstract][Full Text] [Related]
29. Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.
Kwon YC; Kim H; Meyer K; Di Bisceglie AM; Ray R
J Immunol; 2016 Aug; 197(4):1127-36. PubMed ID: 27357152
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the active sites in decay-accelerating factor.
Kuttner-Kondo LA; Mitchell L; Hourcade DE; Medof ME
J Immunol; 2001 Aug; 167(4):2164-71. PubMed ID: 11490001
[TBL] [Abstract][Full Text] [Related]
31. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
32. Co-expression of human complement regulatory proteins DAF and MCP with an IRES-mediated dicistronic mammalian vector enhances their cell protective effects.
Xu L; Zhao Z; Sheng J; Zhu C; Liu H; Jiang D; Mao X; Guo M; Li W
Biochemistry (Mosc); 2008 Sep; 73(9):1025-30. PubMed ID: 18976220
[TBL] [Abstract][Full Text] [Related]
33. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
[TBL] [Abstract][Full Text] [Related]
34. Structure and flexibility of the multiple domain proteins that regulate complement activation.
Kirkitadze MD; Barlow PN
Immunol Rev; 2001 Apr; 180():146-61. PubMed ID: 11414356
[TBL] [Abstract][Full Text] [Related]
35. Molecular remodelling of human CD46 for xenotransplantation: designing a potent complement regulator without measles virus receptor activity.
Begum NA; Murakami Y; Mikata S; Matsumoto M; Hatanaka M; Nagasawa S; Kinoshita T; Seya T
Immunology; 2000 May; 100(1):131-9. PubMed ID: 10809968
[TBL] [Abstract][Full Text] [Related]
36. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
37. CD46 (membrane cofactor protein of complement, measles virus receptor): structural and functional divergence among species (review).
Seya T; Nomura M; Murakami Y; Begum NA; Matsumoto M; Nagasawa S
Int J Mol Med; 1998 May; 1(5):809-16. PubMed ID: 9852300
[TBL] [Abstract][Full Text] [Related]
38. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55.
Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D
J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134
[TBL] [Abstract][Full Text] [Related]
39. Evolutionary history of orthopoxvirus proteins similar to human complement regulators.
Ciulla E; Emery A; Konz D; Krushkal J
Gene; 2005 Aug; 355():40-7. PubMed ID: 16023794
[TBL] [Abstract][Full Text] [Related]
40. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation.
van Beek J; van Meurs M; 't Hart BA; Brok HP; Neal JW; Chatagner A; Harris CL; Omidvar N; Morgan BP; Laman JD; Gasque P
J Immunol; 2005 Feb; 174(4):2353-65. PubMed ID: 15699172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
